These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 7561360

  • 21. Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
    Ogata A, Kitano M, Hashimoto N, Iwasaki T, Hamano T, Kakishita E.
    J Bone Miner Metab; 2002; 20(4):240-2. PubMed ID: 12115071
    [No Abstract] [Full Text] [Related]

  • 22. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma.
    Pittari G, Costi D, Raballo M, Maulucci L, Baroni MC, Mangoni M.
    Acta Biomed; 2006 Aug; 77(2):81-4. PubMed ID: 17172186
    [Abstract] [Full Text] [Related]

  • 23. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N, Colla S, Rizzoli V.
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [Abstract] [Full Text] [Related]

  • 24. Human calcitonin and malignant osteolysis.
    Nuti R, Righi G, Turchetti V, Vattimo A, Lazzaretto R, Martini G.
    Panminerva Med; 1986 Dec; 28(1):5-9. PubMed ID: 3960585
    [No Abstract] [Full Text] [Related]

  • 25. Osteopontin dysregulation and lytic bone lesions in multiple myeloma.
    Robbiani DF, Colon K, Ely S, Ely S, Chesi M, Bergsagel PL.
    Hematol Oncol; 2007 Mar; 25(1):16-20. PubMed ID: 17044113
    [Abstract] [Full Text] [Related]

  • 26. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M, Pogłód R, Pawlikowski J, Maj S, Nasiłowska B.
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [Abstract] [Full Text] [Related]

  • 27. Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients.
    Williams SA, Martin SK, Vincent C, Gronthos S, Zheng T, Atkins GJ, Zannettino AC.
    Br J Haematol; 2010 Aug; 150(3):373-6. PubMed ID: 20408838
    [No Abstract] [Full Text] [Related]

  • 28. Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.
    Arzoo K, Sadeghi S, Pullarkat V.
    N Engl J Med; 2001 Jul 19; 345(3):225. PubMed ID: 11463032
    [No Abstract] [Full Text] [Related]

  • 29. [2 cases of multiple myeloma with osteosclerosis].
    Felder M, Keiser G, Wirth W.
    Schweiz Med Wochenschr; 1979 Nov 17; 109(44):1713-9. PubMed ID: 524105
    [Abstract] [Full Text] [Related]

  • 30. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
    Andersen TL, Søe K, Sondergaard TE, Plesner T, Delaisse JM.
    Br J Haematol; 2010 Feb 17; 148(4):551-61. PubMed ID: 19919653
    [Abstract] [Full Text] [Related]

  • 31. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002 Feb 17; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

  • 32. Pamidronate disodium reduces skeletal complications of multiple myeloma.
    Oncology (Williston Park); 1996 Feb 17; 10(2):253. PubMed ID: 8838269
    [No Abstract] [Full Text] [Related]

  • 33. Managing bone loss in revision total hip arthroplasty: the acetabulum.
    O'Brien DA, Rorabeck CH.
    Instr Course Lect; 2006 Feb 17; 55():263-77. PubMed ID: 16958462
    [Abstract] [Full Text] [Related]

  • 34. [Biochemical monitoring of bone involvement in multiple myeloma].
    Neuwirtová R, Stĕpán J, Pacovský V, Formánková J, Jarolímková E.
    Vnitr Lek; 1983 Jul 17; 29(7):630-7. PubMed ID: 6613030
    [No Abstract] [Full Text] [Related]

  • 35. Single photon bone densitometry in multiple myeloma.
    Bacovský J, Scudla V, Pospísil Z.
    Acta Univ Palacki Olomuc Fac Med; 1999 Jul 17; 142():83-4. PubMed ID: 10743731
    [Abstract] [Full Text] [Related]

  • 36. New diphosphonates to block bone resorption.
    Raisz LG.
    N Engl J Med; 1980 Feb 07; 302(6):347-8. PubMed ID: 6444242
    [No Abstract] [Full Text] [Related]

  • 37. Intravenous pamidronic acid: new indications. Useful palliative treatment for osteolysis.
    Prescrire Int; 1998 Aug 07; 7(36):103-5. PubMed ID: 10342945
    [Abstract] [Full Text] [Related]

  • 38. [Multiple myeloma].
    Abe M.
    Nihon Rinsho; 2009 May 07; 67(5):991-5. PubMed ID: 19432122
    [Abstract] [Full Text] [Related]

  • 39. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M.
    Przegl Lek; 2002 May 07; 59(1):37-42. PubMed ID: 12108045
    [Abstract] [Full Text] [Related]

  • 40. Evidence for the secretion of an osteoclast stimulating factor in myeloma.
    Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE.
    N Engl J Med; 1974 Nov 14; 291(20):1041-6. PubMed ID: 4413338
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.